Merck Ventures Further into Natural Killer Therapies with US$1.9 B Artiva Alliance
By Michelle Liu
Pharma Deals Review: Vol 2021 Issue 2 (Table of Contents)
Published: 13 Feb-2021
DOI: 10.3833/pdr.v2021.i2.2593 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In a move to bolster its immuno-oncology portfolio, Merck & Co...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS